ADPT · NASDAQ · STOCK
Adaptive Biotechnologies (ADPT) Stock Analysis
$26.48
52W $12.00 – $30.74
55/100
$4.24B
-65.0
2.10
Is ADPT Bullish or Bearish?
Bullish.
Innellis AI committee rates Adaptive Biotechnologies Corporation (ADPT) Buy with a composite score of 55/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +19.65 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -0.35 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 50.1% yoy -- genuine top-line momentum. Value Analyst remains cautious — price-to-book of 11.3x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Revenue growing 50.1% YoY -- genuine top-line momentum — Growth
- 4 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price-to-book of 11.3x prices in significant intangible value — Value
- ROE of only -32.6% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 18.9% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
55/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 63%
of 192 Healthcare peers
Value Analyst
bearish
30
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− Price-to-book of 11.3x prices in significant intangible value
Growth Analyst
bullish
83
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 50.1% YoY -- genuine top-line momentum
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst
bearish
35
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 18.9% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 55.4 to 55.4.
- New bearish signals: 1 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
Analyst-level changes:
- Risk Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
41.8
Neutral
MACD Histogram
-0.393
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.24
Inside Bands
Price vs Moving Averages
EMA 9
$27.28
Below
EMA 21
$27.23
Below
EMA 50
$25.77
Above
EMA 200
$20.18
Above
Fundamental Analysis
Valuation
67
Growth
94
Profitability
25
Financial Health
50
Cash Flow
15
Valuation
P/E Ratio
-65.0×
P/B Ratio
29.23×
PEG Ratio
-1.29
Dividend Yield
0.00%
52W High
$30.74
52W Low
$12.00
Quality & Growth
ROE
-2719.4%
ROA
-1160.4%
Gross Margin
7543.6%
Operating Margin
-1215.9%
Revenue Growth YoY
—
Debt / Equity
2.87
AI Fundamental Assessment
P/E ratio of -65.0 (inexpensive relative to a 15-40x range); Price-to-book of 29.2x; PEG ratio of -1.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -27.2%; Return on assets of -11.6%; Net margin of -20.7%; Gross margin of 75.4%; Current ratio of 4.79 (healthy short-term liquidity); Debt-to-equity of 2.87; Free cash flow per share is negative (-0.15); Most recent quarter beat estimates by 26.7%; 4 consecutive earnings beats; EPS growth accelerating (-33.3% -> +16.7% QoQ); Analyst estimates rising over recent quarters
Get the Full ADPT Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →